GT199900156A - Administraciòn de agente activo en polvo seco. - Google Patents

Administraciòn de agente activo en polvo seco.

Info

Publication number
GT199900156A
GT199900156A GT199900156A GT199900156A GT199900156A GT 199900156 A GT199900156 A GT 199900156A GT 199900156 A GT199900156 A GT 199900156A GT 199900156 A GT199900156 A GT 199900156A GT 199900156 A GT199900156 A GT 199900156A
Authority
GT
Guatemala
Prior art keywords
active agent
dry powder
administration
hygroscopic
development
Prior art date
Application number
GT199900156A
Other languages
English (en)
Inventor
Andrew Clark
Mei Chang Kuo
Cecily Lalor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199900156A publication Critical patent/GT199900156A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Abstract

LA PRESENTE INVENCIÒN SE RELACIONA CON LA ADMINISTRACIÒN MEJORADA DE UNA FORMULACIÒN DE AGENTE ACTIVO EN POLVO SECO HACIA LAS PROFUNDIDADES DEL PULMÒN. MÀS ESPECÌFICAMENTE, LA INVENCIÒN SE REFIERE A PARTÌCULAS DE POLVO SECO AEROSOLIZABLES QUE, AL SER INHALADAS, SON RESISTENTES AL DESARROLLO HIGROSCÒPICO. ESTA CARACTERÌSTICA DEL POLVO (SU RESISTENCIA AL DESARROLLO HIGROSCÒPICO) PERMITE QUE UNA MAYOR PROPORCIÒN DE LAS PARTÌCULAS INHALADAS LLEGUE A LA PROFUNDIDAD DEL PULMÒN, AUMENTANDO ASÌ LA BIODISPONIBLIDAD DE UN AGENTE ACTIVO ADMINISTRADO AL PULMÒN.
GT199900156A 1998-09-14 1999-09-14 Administraciòn de agente activo en polvo seco. GT199900156A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10016398P 1998-09-14 1998-09-14

Publications (1)

Publication Number Publication Date
GT199900156A true GT199900156A (es) 2001-03-07

Family

ID=22278404

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199900156A GT199900156A (es) 1998-09-14 1999-09-14 Administraciòn de agente activo en polvo seco.

Country Status (44)

Country Link
EP (1) EP1117442A1 (es)
JP (1) JP2002524535A (es)
KR (1) KR20010075063A (es)
CN (1) CN1317977A (es)
AP (1) AP1374A (es)
AR (1) AR022090A1 (es)
AU (1) AU753014B2 (es)
BG (1) BG105430A (es)
BR (1) BR9913722A (es)
CA (1) CA2343920A1 (es)
CO (1) CO5130023A1 (es)
CZ (1) CZ2001829A3 (es)
DZ (1) DZ2892A1 (es)
EA (1) EA003476B1 (es)
EE (1) EE200100151A (es)
GE (1) GEP20043257B (es)
GT (1) GT199900156A (es)
HK (1) HK1042231A1 (es)
HN (1) HN1999000159A (es)
HR (1) HRP20010189A2 (es)
HU (1) HUP0103837A3 (es)
ID (1) ID28845A (es)
IL (2) IL141562A0 (es)
IS (1) IS5878A (es)
LT (1) LT4897B (es)
LV (1) LV12658B (es)
MA (1) MA25590A1 (es)
MY (1) MY129282A (es)
NO (1) NO20011251L (es)
NZ (1) NZ510168A (es)
OA (1) OA11781A (es)
PA (1) PA8481901A1 (es)
PE (1) PE20001061A1 (es)
PL (1) PL195574B1 (es)
SA (1) SA99200718B1 (es)
SK (1) SK3442001A3 (es)
TN (1) TNSN99173A1 (es)
TR (1) TR200101182T2 (es)
TW (1) TWI226248B (es)
UA (1) UA76085C2 (es)
UY (1) UY25711A1 (es)
WO (1) WO2000015262A1 (es)
YU (1) YU24201A (es)
ZA (1) ZA200101995B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630121B1 (en) 1999-06-09 2003-10-07 The Regents Of The University Of Colorado Supercritical fluid-assisted nebulization and bubble drying
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6737042B2 (en) * 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
PL373780A1 (en) 2002-02-25 2005-09-19 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
WO2004004798A2 (en) * 2002-07-03 2004-01-15 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
CA2511385A1 (en) * 2002-12-19 2004-07-22 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
HUE042304T2 (hu) * 2004-04-23 2019-06-28 Cydex Pharmaceuticals Inc DPI készítmény, amely szulfoalkil-éter-ciklodextrint tartalmaz
EP1853544A4 (en) 2005-02-24 2010-06-16 Diffusion Pharmaceuticals Llc TRANSCAROTENOIDS AND THEIR SYNTHESIS, THEIR PREPARATION AND USES THEREOF
JPWO2006095788A1 (ja) * 2005-03-09 2008-08-14 小野薬品工業株式会社 粒子およびその粒子を含有する製剤
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
JP5465432B2 (ja) 2005-10-26 2014-04-09 サイデックス・ファーマシューティカルズ・インコーポレイテッド スルホアルキルエーテルシクロデキストリン組成物及びその製造方法
US20100269819A1 (en) * 2006-08-14 2010-10-28 Sievers Robert E Human Powered Dry Powder Inhaler and Dry Powder Inhaler Compositions
WO2008050847A1 (fr) * 2006-10-25 2008-05-02 Dainippon Sumitomo Pharma Co., Ltd. Préparation granulaire non agglutinante
EP1925295A1 (de) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stabile Pulverformulierung enthaltend ein Anticholinergikum
AU2008246305B2 (en) 2007-04-13 2013-03-21 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
US8206751B2 (en) 2007-10-31 2012-06-26 Diffusion Pharmaceuticals Llc Class of therapeutics that enhance small molecule diffusion
ES2661215T3 (es) * 2009-05-20 2018-03-28 Aeras Composiciones víricas; inmunógenas; secadas por pulverización; estables
EP2445339B1 (en) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Diffusion enhancing compound and its use with a thrombolytic
ES2654945T3 (es) 2010-06-02 2018-02-15 Diffusion Pharmaceuticals Llc Formulaciones orales de carotenoides trans bipolares
AU2013255885C1 (en) * 2012-05-03 2018-04-26 Janssen Sciences Ireland Uc Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections
WO2014074797A1 (en) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
US20180043585A9 (en) * 2013-09-20 2018-02-15 Virginia Commonwealth University Delivery of particles using hygroscopic excipients
CN107106641B (zh) 2014-10-31 2021-12-21 葛兰素史密斯克莱知识产权发展有限公司 粉末制剂
CN109152839A (zh) 2016-03-24 2019-01-04 扩散药品有限公司 双极性反式类胡萝卜素连同化疗和放射治疗在治疗癌症中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
ES2177544T3 (es) * 1992-06-12 2002-12-16 Teijin Ltd Polvo ultrafinno para inhalar y metodo para su preparacion.
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
ES2236832T3 (es) * 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant

Also Published As

Publication number Publication date
EA200100300A1 (ru) 2001-10-22
TWI226248B (en) 2005-01-11
NZ510168A (en) 2003-09-26
PA8481901A1 (es) 2002-04-25
NO20011251L (no) 2001-04-17
HUP0103837A3 (en) 2002-11-28
ID28845A (id) 2001-07-05
UY25711A1 (es) 1999-11-17
HRP20010189A2 (en) 2005-04-30
OA11781A (en) 2005-07-26
SK3442001A3 (en) 2001-11-06
AP1374A (en) 2005-02-28
WO2000015262A1 (en) 2000-03-23
LV12658B (lv) 2001-09-20
DZ2892A1 (fr) 2003-12-15
CZ2001829A3 (cs) 2001-09-12
TNSN99173A1 (fr) 2005-11-10
SA99200718B1 (ar) 2006-11-04
HN1999000159A (es) 1999-11-11
CO5130023A1 (es) 2002-02-27
BG105430A (en) 2001-12-29
LT2001021A (en) 2001-11-26
LT4897B (lt) 2002-02-25
LV12658A (lv) 2001-05-20
AP2001002093A0 (en) 2001-03-31
NO20011251D0 (no) 2001-03-13
YU24201A (sh) 2003-08-29
IL141562A (en) 2007-07-24
EE200100151A (et) 2002-06-17
AR022090A1 (es) 2002-09-04
MY129282A (en) 2007-03-30
IL141562A0 (en) 2002-03-10
AU753014B2 (en) 2002-10-03
JP2002524535A (ja) 2002-08-06
PE20001061A1 (es) 2000-10-08
MA25590A1 (fr) 2002-12-31
EP1117442A1 (en) 2001-07-25
HUP0103837A2 (hu) 2002-05-29
GEP20043257B (en) 2004-06-25
PL346768A1 (en) 2002-02-25
TR200101182T2 (tr) 2001-09-21
AU6039799A (en) 2000-04-03
PL195574B1 (pl) 2007-10-31
KR20010075063A (ko) 2001-08-09
CN1317977A (zh) 2001-10-17
CA2343920A1 (en) 2000-03-23
ZA200101995B (en) 2002-03-11
HK1042231A1 (zh) 2002-08-09
BR9913722A (pt) 2001-05-29
EA003476B1 (ru) 2003-06-26
UA76085C2 (en) 2006-07-17
IS5878A (is) 2001-03-05

Similar Documents

Publication Publication Date Title
GT199900156A (es) Administraciòn de agente activo en polvo seco.
DK1318788T3 (da) Nanopartikulær fastdosissammensætninger
CY1110376T1 (el) Χρηση μιας συνθεσης που περιλαμβανει φορμοτερολη και βουδεσονιδη για την προληψη απο ή τη θεραπευτικη αντιμετωπιση μιας οξειας καταστασης ασθματος
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
BR0212950A (pt) Formas de dosagens compósitas tendo uma porção inserida
WO2003057135A3 (en) Aqueous compositions containing metronidazole
BR0212475A (pt) Composições farmacêuticas
AR034346A1 (es) Capsulas para inhalacion
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
DE59904648D1 (de) Medizinische aerosolformulierungen
BR9917089A (pt) Composições e métodos para distribuição mucosal
ATE485070T1 (de) Inhalator für pulverförmige zubereitungen
DE69922175D1 (de) Pulverinhalator
ATE410151T1 (de) Kapseln für inhalatoren
BR9810495A (pt) Composição farmacêutica
DE69811278T2 (de) Gegen magensaft geschützte omeprazol-mikrogranülen, herstellungsverfahren und pharmazeutische zubereitungen
IS8334A (is) Æxilseyðandi samsetningar sem samanstanda af defíbrótíði stöku eða blönduðu með öðrum æxliseyðandi miðlum
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
NO20052408L (no) Farmasoytisk formulering av olanzapin
DK0930077T3 (da) Cyclodextrinpræparater indeholdende et avermectin- eller milbemycinderivat
AR036474A1 (es) Uso de una combinacion de compuestos en un inhalador de polvo seco
DE69933671D1 (de) Adenosin a1 antagonisten gegen männliche sterilität
ATE207492T1 (de) Difluoroavermectin-derivate
PA8459501A1 (es) Formulaciones parasiticidas